Revance Therapeutics (RVNC) Price Target Raised to $54.00
Revance Therapeutics (NASDAQ:RVNC) had its price target boosted by Mizuho from $37.00 to $54.00 in a research report released on Wednesday, Marketbeat.com reports. Mizuho currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on the company. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the stock a buy rating in a research report on Wednesday, November 29th. Zacks Investment Research cut Revance Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 7th. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $28.00 price objective on shares of Revance Therapeutics in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $42.11.
Shares of Revance Therapeutics (NASDAQ RVNC) opened at $34.65 on Wednesday. Revance Therapeutics has a 1 year low of $15.90 and a 1 year high of $37.20.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same period in the previous year, the business posted ($0.64) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts predict that Revance Therapeutics will post -3.73 EPS for the current year.
In other Revance Therapeutics news, Director Mark J. Foley purchased 20,000 shares of Revance Therapeutics stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average cost of $26.96 per share, with a total value of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at $161,760. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total value of $179,208.00. Following the completion of the sale, the chief executive officer now directly owns 148,450 shares of the company’s stock, valued at $3,500,451. The disclosure for this sale can be found here. Insiders sold a total of 44,026 shares of company stock valued at $1,135,234 over the last three months. Insiders own 18.86% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Revance Therapeutics in the 3rd quarter valued at approximately $144,000. Bank of America Corp DE increased its stake in Revance Therapeutics by 29.5% in the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 1,651 shares in the last quarter. Legal & General Group Plc increased its stake in Revance Therapeutics by 8.1% in the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 438 shares in the last quarter. Trexquant Investment LP purchased a new position in Revance Therapeutics in the 2nd quarter valued at approximately $231,000. Finally, Voya Investment Management LLC purchased a new position in Revance Therapeutics in the 2nd quarter valued at approximately $274,000. 88.70% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Revance Therapeutics (RVNC) Price Target Raised to $54.00” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/10/revance-therapeutics-rvnc-price-target-raised-to-54-00.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.